Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch Health Companies Inc. Common Stock (TSX:BHC)

11.57 +0.10 (+0.87%)
Delayed Quote Updated: 10:11 AM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch Health Companies Inc. Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
Via ACCESSWIRE
News headline image
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
Via ACCESSWIRE
News headline image
Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
Via ACCESSWIRE
News headline image
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
Via ACCESSWIRE
News headline image
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
Via ACCESSWIRE
News headline image
Bausch Health Announces First Quarter 2024 Results
Via ACCESSWIRE
News headline image
Salix Announces 2024 Gastrointestinal Health Scholars Program
Via ACCESSWIRE
News headline image
CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
Via ACCESSWIRE
News headline image
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
Via ACCESSWIRE
News headline image
Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
Via ACCESSWIRE
News headline image
Bausch Health to Announce First-Quarter 2024 Results on May 2
Via ACCESSWIRE
News headline image
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
Via ACCESSWIRE
News headline image
Solta Medical’s Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
Via ACCESSWIRE
News headline image
Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis
Via ACCESSWIRE
News headline image
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
Via ACCESSWIRE
News headline image
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
Via ACCESSWIRE
News headline image
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
Via ACCESSWIRE
News headline image
Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations
Via ACCESSWIRE
News headline image
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
Via ACCESSWIRE
News headline image
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
Via ACCESSWIRE
News headline image
Bausch Health Companies to Present at Cowen Annual Health Care Conference
Via ACCESSWIRE
News headline image
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
Via ACCESSWIRE
News headline image
Bausch Health Announces Board Refreshment
Via ACCESSWIRE
News headline image
Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22
Via ACCESSWIRE
News headline image
CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.
Via ACCESSWIRE
News headline image
Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute
Via ACCESSWIRE
News headline image
DUOBRII(TM) Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec’s Public Drug Plan
Via ACCESSWIRE
News headline image
Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day
Via ACCESSWIRE
News headline image
The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
Via ACCESSWIRE
News headline image
CORRECTION BY SOURCE: The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
Via ACCESSWIRE
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.